CINGW — Cingulate Inc.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for CINGW in the TickerWise workspace.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 13
• Website: https://www.cingulate.com

Latest SEC filings for CINGW

• 2026-07-15S-8
• 2026-04-27EFFECT
• 2026-04-14S-3
• 2026-04-14S-3
• 2026-03-27EFFECT
• 2026-03-25EFFECT
• 2026-03-23S-3/A
• 2026-03-23S-3/A
• 2026-03-20S-3

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.